AHMAD, Parwez, Jiří ŠÁNA, Marek SLÁVIK, Dominik GURÍN, Lenka RADOVÁ, Natalia Anna GABŁO, Tomáš KAZDA, Pavel SMILEK, Zuzana HORÁKOVÁ, Břetislav GÁL, Markéta HERMANOVÁ, Pavel ŠLAMPA and Ondřej SLABÝ. MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy. CANCER GENOMICS & PROTEOMICS. ATHENS: INT INST ANTICANCER RESEARCH, 2019, vol. 16, No 2, p. 139-146. ISSN 1109-6535. Available from: https://dx.doi.org/10.21873/cgp.20119.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy
Authors AHMAD, Parwez (356 India, belonging to the institution), Jiří ŠÁNA (203 Czech Republic, belonging to the institution), Marek SLÁVIK (703 Slovakia, belonging to the institution), Dominik GURÍN (203 Czech Republic, belonging to the institution), Lenka RADOVÁ (203 Czech Republic, belonging to the institution), Natalia Anna GABŁO (616 Poland, belonging to the institution), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Pavel SMILEK (203 Czech Republic, belonging to the institution), Zuzana HORÁKOVÁ (203 Czech Republic, belonging to the institution), Břetislav GÁL (203 Czech Republic, belonging to the institution), Markéta HERMANOVÁ (203 Czech Republic, belonging to the institution), Pavel ŠLAMPA (203 Czech Republic, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution).
Edition CANCER GENOMICS & PROTEOMICS, ATHENS, INT INST ANTICANCER RESEARCH, 2019, 1109-6535.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Greece
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.280
RIV identification code RIV/00216224:14740/19:00108511
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.21873/cgp.20119
UT WoS 000463451200004
Keywords in English Head and neck cancer; microRNA; miR-15b-5p; locoregional control; radiotherapy; IMRT
Tags 14110112, 14110126, 14110812, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 9/6/2020 13:07.
Abstract
Background/Aim: Head and neck cancers are a heterogenous group of epithelial tumors represented mainly by squamous cell carcinomas (HNSCC), which are the sixth most common type of cancer worldwide. Surgery together with radiotherapy (RT) is among the basic treatment modalities for most HNSCC patients. Various biomarkers aiming to predict patients' response to RT are currently investigated. The reason behind this effort is, on one hand, to distinguish radioresistant patients that show weak benefit from RT and, on the other hand, reduce the ionizing radiation dose in less aggressive radiosensitive HNSCC with possibly less acute or late toxicity. Materials and Methods: A total of 94 HNSCC patients treated by definitive intensity-modulated radiotherapy were included in our retrospective study. We used a global expression analysis of microRNAs (miRNAs) in 43 tumor samples and validated a series of selected miRNAs in an independent set of 51 tumors. Results: We identified miR-15b-5p to be differentially expressed between patients with short and long time of locoregional control (LRC). Kaplan-Meier analysis confirmed that HNSCC patients with higher expression of miR-15b-5p reach a significantly longer locoregional relapsefree survival compared to patients expressing low levels. Finally, multivariable Cox regression analysis revealed that miR-15b-5p is an independent predictive biomarker of LRC in HNSCC patients (HR=0.25 ; 95% CI=0.05-0.78; p<0.016). Conclusion: miR-15b-5p represents a potentially helpful biomarker for individualized treatment decisions concerning the management of HNSCC patients.
Links
NV15-31627A, research and development projectName: Možnosti molekulárně řízené radikální radioterapie nebo radiochemoterapie dle profilu mikroRNA u pacientů se spinocelulárními karcinomy hlavy a krku.
PrintDisplayed: 26/4/2024 04:57